Posts tagged GenomeDx.
Blogs
2 minute read
GenomeDx Biosciences Corp., which markets a genomic test (Decipher®) intended to assess the aggressiveness of prostate cancer, has agreed to pay $1.99 million to the U.S. Department of Justice to resolve allegations that it violated the False Claims Act (31 U.S.C. §§ 3729 et seq.)(“FCA”) by submitting claims to Medicare for tests conducted to evaluate treatment options for men after prostate surgery.
The government and a whistleblower alleged that between September 2015 and June 2017, GenomeDx knowingly submitted Medicare reimbursement claims for the Decipher® test ...
Blog Editors
Recent Updates
- Medicaid Behavioral Health Investigations and Payment Suspensions in D.C. Are Increasing – How Providers Can Limit Risk
- ‘Emilie’ Is Not a Psychiatrist: Pennsylvania Board of Medicine Alleges Unlawful Practice of Medicine by an AI Chatbot
- DOJ’s West Coast Strike Force to Target Health Care Fraud in Arizona, Nevada, and Northern California
- DOJ FOCUS Initiative Prioritizes “High Quality” Data Miner Actions by FCA Whistleblowers
- FDA Proposal Would Leave Semaglutide, Tirzepatide, and Liraglutide Off 503B Bulks List